---

Cited by CrossRef: 6

---

1- Naganuma M, Motooka Y, Sasaoka S, Hatahira H, Hasegawa S, Fukuda A, Nakao S, Shimada K, Hirade K, Mori T, Yoshimura T, Kato T, Nakamura M. Analysis of adverse events of renal impairment related to platinum-based compounds using the Japanese Adverse Drug Event Report database. SAGE Open Medicine. 2018;6:205031211877247 [Crossref]

---

2- Mense E, Smit A, Crul M, Franssen E. The effect of rapid infusion of cisplatin on nephrotoxicity in patients with lung carcinoma. J Clin Pharm Ther. 2018; [Crossref]

---

3- Pemetrexed. Reactions Weekly. 2017;1647(1):237 [Crossref]

---

4- Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, Domine M, Clingan P, Hochmair M, Powell S, Cheng S, Bischoff H, Peled N, Grossi F, Jennens R, Reck M, Hui R, Garon E, Boyer M, Rubio-Viqueira B, Novello S, Kurata T, Gray J, Vida J, Wei Z, Yang J, Raftopoulos H, Pietanza M, Garassino M. Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer. N Engl J Med. 2018;378(22):2078 [Crossref]

---

5- Middleton G, Gridelli C, De Marinis F, Pujol J, Reck M, Ramlau R, Parente B, Pieters T, Visseren-Grul C, San Antonio B, John W, Zimmermann A, Chouaki N, Paz-Ares L. Evaluation of changes in renal function in PARAMOUNT: a phase III study of maintenance pemetrexed plus best supportive care versus placebo plus best supportive care after induction treatment with pemetrexed plus cisplatin for advanced nonsquamous non-small-cell lung cancer. Current Medical Research and Opinion. 2018;34(5):865 [Crossref]

---